选择抗逆转录病毒疗法对体重增加的影响很小
Henning Drechsler1,2, Colby Ayers1, Ikwo Oboho1,2
1Department of Medicine, University of Texas Southwestern.
AIDS (London, England)
|June 4, 2024
概括
选择初始抗逆转录病毒疗法 (ART) 对体重增加的影响最小. 整合酶抑制剂 (INSTIs) 或二阿拉芬胺 (TAF) 与体重变化无关,与埃法维伦兹 (EFV) 和二二 fumarate (TDF) 不同.
科学领域:
- 艾滋病毒/艾滋病治疗治疗
- 药理学 药理学是指药理学的学科.
- 代谢健康 代谢健康
背景情况:
- 抗逆转录病毒疗法 (ART) 方案,特别是那些使用整合酶抑制剂 (INSTIs) 和氧胺 (TAF) 的疗法,与增加体重增加有关.
- 之前的研究还没有明确区分不同""药物 (蛋白酶抑制剂[PI],非核酸逆转录酶抑制剂[NNRTIs],INSTIs) 与核酸逆转录酶抑制剂 (NRTIs) 对体重变化的影响.
研究的目的:
- 研究选择初始ART治疗方案与身体质量指数 (BMI) 在三年内增加之间的关联.
- 为了区分各种""药物和核酸逆转录酶抑制剂 (NRTIs) 在开始ART的未经治疗的个体中的体重增加效应.
主要方法:
- 一项队列研究分析了2008年至2022年期间开始ART的4194名未服用抗逆转录病毒药物的患者的BMI变化.
- 用通用估计方程 (GEE) 和非线性混合模型来评估ART选择和BMI增长之间的关联,调整为人口,艾滋病毒和物质使用变量.
- 如果患者在三年随访期间改变了他们的ART治疗方案,则会受到审查.
主要成果:
- 在三年内,BMI的中位数增长为1.9kg/m2.
- 在预测的BMI变化中,ART治疗方案的类型仅占了9%.
- 埃法维伦兹 (EFV) 和特诺福维尔二氧化 fumarate (TDF) 独立地与较低的体重增加有关;在INSTIs,PI,rilpivirine,TAF或abacavir之间没有发现显著差异.
结论:
- 最初的ART选择对整体体重增加的影响有限.
- INSTIs和TAF没有独立地与体重变化相关,而EFV和TDF与体重增加较少相关.
相关概念视频
Retrovirus Life Cycles
45.8K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
45.8K
Drug Therapy
42
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
42
Antidepressant Drugs: Overview
444
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
444
Insulin: Dosing Regimen and Adverse Effects
166
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
166
Obesity
453
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
453
Oral Hypoglycemic Agents: Biguanides and Glitazones
189
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
189


